Biodesix’ VeriStrat® Test Now Covered By Humana, Medical Mutual of Ohio, PreferredOne

Monday, October 31, 2016

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix announced today that Humana, Medical Mutual of Ohio and PreferredOne health plans have established reimbursement coverage of the VeriStrat®test, Biodesix’ proteomic blood test for patients with non-small cell lung cancer (NSCLC). VeriStrat has received positive coverage decisions from Humana, Medical Mutual of Ohio, and PreferredOne and as a result of these coverage changes, an additional 11.5 million Americans now have insurance coverage for VeriStrat. 

Colorado BioScience Association to Celebrate the State’s Breakthrough Companies and Contributors at Awards Dinner

Thursday, October 27, 2016


Baby Genes Partners with The Quinn Madeline Foundation for Diagnostic Carrier Screening Program

Monday, October 24, 2016

FOR IMMEDIATE RELEASE – October 24, 2016 

Colorado Therapeutics Receives 510(k) Clearance for a Novel Xenograft Implant for Soft Tissue Repairs

Friday, October 21, 2016

BROOMFIELD, CO – October 21, 2016 – Colorado Therapeutics LLC, a privately held medical device company with a proprietary technology platform for the production of innovative cross-linked tissue products, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for a novel xenogenic biologic tissue matrix. The Colorado Therapeutics xenograft implant is intended to be used for implantation to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue membranes. This unique xenograft product has been developed to combine the benefits of currently available biologic and synthetic products while being packaged in a dry state, making it a ready-for-use, off-the-shelf, biologic tissue matrix. Colorado Therapeutics, now with 510(k) FDA clearance, has the right to commence manufacturing, marketing and sales of the product in the United States and its possessions subject to FDA jurisdiction. 

Green Sun Medical Wins $250,000 Medtech Innovator Award at AdvaMed

Wednesday, October 19, 2016

Colorado-based Green Sun Medical just won the $250,000 Medtech Innovator Award at AdvaMed.  

Medical Discovery And Fighting Disease Are Non-Partisan

Tuesday, October 18, 2016

For policymakers and candidates willing to embrace public policies that help support the development of new treatments and cures, a unique proposition exists: Colorado voters will reward those who make medical discovery a key part of their platform. 

Symbios Announces Patent Award for Plasma Oxidation Technology

Tuesday, October 18, 2016

Symbios Technologies, Inc., a world-leading developer of dynamic aqueous plasma technology platforms, announced today that United States Patent and Trademark Office (USPTO) has awarded the company a patent for its tubular high-density plasma reactor, U.S. Patent # 9,346,691. 

Flagship’s computational Tissue Analysis (cTA™) tools support Summit’s DMD drug development

Tuesday, October 18, 2016

Flagship develops cTA™ tools and duplex IHC assays for muscle biopsy evaluation in support of disease-modifying therapies for Duchenne muscular dystrophy 

Webinar: NO on Amendment 69 (Colorado Care)

Monday, October 17, 2016

On Thursday, October 13, the Colorado BioScience Association, in conjunction with CoBiz Financial, Coloradans for Coloradans and the Denver Metro Chamber of Commerce, hosted a webinar to share the reasons for opposing Amendment 69, Colorado Care. 

A brighter experience at the dental office for 75,000 patients thanks to a Denver startup

Wednesday, October 12, 2016